Already cleared in the US for use in soft tissue ablation, Pulse Biosciences is looking to add AF to CellFX’s indication list ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Cardiac ablation has emerged as a transformative medical procedure for patients struggling with irregular heart rhythms particularly atrial fibrillation AFib By targeting and eliminating problematic a ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

CardioFocus today announced the publication of 12-month data from a study of its pulsed field ablation (PFA) system for ...

The following is a summary of “Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes,” published in the ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed ...